Publications

Detailed Information

Reciprocal Immunohistochemical Expression of Sodium/Iodide Symporter and Hexokinase I in Primary Thyroid Tumors with Synchronous Cervical Metastasis

DC Field Value Language
dc.contributor.authorJung, Young Ho-
dc.contributor.authorHah, J. Hun-
dc.contributor.authorSung, Myung-Whun-
dc.contributor.authorKim, Kwang Hyun-
dc.contributor.authorJeon, Yoon Kyung-
dc.contributor.authorCho, Soo Youn-
dc.date.accessioned2012-06-04T05:52:15Z-
dc.date.available2012-06-04T05:52:15Z-
dc.date.issued2009-03-
dc.identifier.citationLARYNGOSCOPE; Vol.119 3; 541-548ko_KR
dc.identifier.issn0023-852X-
dc.identifier.urihttps://hdl.handle.net/10371/76785-
dc.descriptionPresented at the 2007 Annual Meeting (April 28 and 29, 2007) of
The American Head and Neck Society during the Combined Otolaryngology
Society Meetings (COSM) in San Diego, California, U.S.A.
ko_KR
dc.description.abstractObjectives/Hypothesis: Sodium/iodide symporter (NIS) is a glycoprotein which is related to the concentration of radioiodine in thyroid cancer. Glucose transporter-1 (Glut-1) and hexokinases (HK) are glycoproteins related to glucose metabolism (i.e., uptake and phosphorylation) in various cancers. The aim of this study was to determine the immunohistochemical patterns of expression and mutual relationships between NIS, Glut-1, HK I, and HK II in primary thyroid tumors and synchronous cervical metastatic tumors. Study Design: Retrospective experimental study. Methods: Nine cases of follicular carcinomas, sixteen cases of papillary carcinomas, and four cases of anaplastic carcinomas were included. The immunohistochemical staining intensities were categorized (scored) as negative (0), weak (1), positive (2), or strongly positive (3) and dichotomized as a negative/weak (scores 0 or 1) or positive expression (scores 2 or 3). Results: NIS had a positive expression in good prognostic types of thyroid carcinomas, such as follicular carcinomas, more often, while having a positive expression in poor prognostic types of thyroid carcinomas, such as anaplastic carcinomas (P = .033) less of ten; HK I had the opposite pattern of expression (P = .033). Primary thyroid tumors and corresponding synchronous cervical metastatic tumors had a similar pattern of expression for NIS, HK I, and HK II. NIS had a reciprocal relationship with HK I as compared to Glut-1 with respect to staining intensity on each primary tumor (P = .040). Conclusion: Reciprocal staining pattern of NIS and HK I on primary tumors is related to the staining pattern of NIS and HK I on synchronous as well as occult cervical metastatic tumors.ko_KR
dc.language.isoenko_KR
dc.publisherJOHN WILEY & SONS INCko_KR
dc.subjectThyroidko_KR
dc.subjecthexokinaseko_KR
dc.subjectglucose transporterko_KR
dc.subjectthyroid carcinomako_KR
dc.subjectsodium/iodide symporterko_KR
dc.titleReciprocal Immunohistochemical Expression of Sodium/Iodide Symporter and Hexokinase I in Primary Thyroid Tumors with Synchronous Cervical Metastasisko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor정영호-
dc.contributor.AlternativeAuthor성명훈-
dc.contributor.AlternativeAuthor김광현-
dc.contributor.AlternativeAuthor조수윤-
dc.contributor.AlternativeAuthor전윤경-
dc.identifier.doi10.1002/lary.20073-
dc.citation.journaltitleLARYNGOSCOPE-
dc.description.citedreferenceElisei R, 2006, J CLIN ENDOCR METAB, V91, P2389, DOI 10.1210/jc.2005-2480-
dc.description.citedreferenceShindo M, 2006, ARCH OTOLARYNGOL, V132, P650-
dc.description.citedreferenceYasuda M, 2005, ONCOL REP, V14, P1499-
dc.description.citedreferenceTian M, 2005, ANN NUCL MED, V19, P335-
dc.description.citedreferenceMatsuzu K, 2005, THYROID, V15, P545-
dc.description.citedreferenceTohma T, 2005, HEPATO-GASTROENTEROL, V52, P486-
dc.description.citedreferenceSchmitz G, 2005, NUKLEARMED-NUCL MED, V44, P86-
dc.description.citedreferenceHooft L, 2005, J CLIN ENDOCR METAB, V90, P328, DOI 10.1210/jc.2004-0779-
dc.description.citedreferenceKim MK, 2004, ARCH OTOLARYNGOL, V130, P1214-
dc.description.citedreferenceMatsuzu K, 2004, THYROID, V14, P806-
dc.description.citedreferenceLacroix L, 2004, J CLIN ENDOCR METAB, V89, P1423, DOI 10.1210/jc.2003-030542-
dc.description.citedreferenceBAKER CH, 2004, CURR DRUG TARGETS IM, V4, P167-
dc.description.citedreferenceTian M, 2004, EUR J NUCL MED MOL I, V31, P5, DOI 10.1007/s00259-003-1316-9-
dc.description.citedreferenceSchonberger J, 2002, THYROID, V12, P747-
dc.description.citedreferenceCastro MR, 2001, J CLIN ENDOCR METAB, V86, P5627-
dc.description.citedreferenceSarafian V, 2001, ANN ENDOCRINOL-PARIS, V62, P230-
dc.description.citedreferenceMin JJ, 2001, EUR J NUCL MED, V28, P639-
dc.description.citedreferenceMIN JJ, 2001, J NUCL MED S, V42, P133-
dc.description.citedreferencePark HJ, 2000, THYROID, V10, P211-
dc.description.citedreferenceFiletti S, 1999, EUR J ENDOCRINOL, V141, P443-
dc.description.citedreferenceCaillou B, 1998, J CLIN ENDOCR METAB, V83, P4102-
dc.description.citedreferenceArturi F, 1998, J CLIN ENDOCR METAB, V83, P2493-
dc.description.citedreferenceSaito T, 1998, J CLIN INVEST, V101, P1296-
dc.description.tc1-
Appears in Collections:
Files in This Item:
There are no files associated with this item.

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share